MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, and the Asia Pacific.
The last earnings update was 20 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether MedMira is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MedMira has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
MedMira. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
MedMira's earnings available for a low price, and how does
this compare to other companies in the same industry?
MedMira has negative assets, we can't compare the value of its assets to the DE Medical Equipment industry average.
Take a look at our analysis of 47M’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MedMira's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedMira has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare MedMira's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare MedMira's earnings growth to the Germany market average as no estimate data is available.
Unable to compare MedMira's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if MedMira is high growth as no earnings estimate data is available.
Unable to determine if MedMira is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
MedMira's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Hermes Chan Co-Founded MedMira Inc. and has been its President since 2000 and Chief Executive Officer since July 24, 2006. Mr. Chan has been the Chief Executive Officer and President of MedMira Laboratories Inc. of MedMira Inc. since July 2006. He served as the Chief Operating Officer of MedMira Inc. since 2000 and MedMira Laboratories Inc. since July 2006. He served as Vice Chairman of MedMira Inc. since 1994. Prior to being appointed as Senior Vice President in 1997, Mr. Chan served as General Manager and as a research scientist with MedMira Laboratories Inc. Prior to joining MedMira Laboratories Inc., Mr. Chan served as a research scientist with Octopus Diagnostic Research, a private diagnostics company located in Wolfville, Nova Scotia. He has been a Director of MedMira Inc. since March 13, 2000.
Hermes's compensation has been consistent with company performance over the past year.
Hermes's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the MedMira management team is over 5 years, this suggests they are a seasoned and experienced team.
Chief Financial Officer
Head of Commercialization and Senior Director of Sales & Marketing
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the MedMira board of directors is less than 3 years, this suggests a new board.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, and the Asia Pacific. The company’s research is focused on specific areas of the diagnostics market, such as rapid, point-of-care, and in vitro sectors. It offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. The company also provides Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; and Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis. In addition, it offers Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its products through a network of medical distributors and strategic business development partners with customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care facilities, governments, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of OnSite Lab Holdings AG.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.